ClinicalTrials.gg
CompletedNCT01108783Updated Apr 5, 2012

A Phase III Efficacy Study of the Symptomatic Treatment of Seasonal Allergic Rhinitis With Bilastine

A Phase 3 interventional study of Bilastine and Desloratadine in Seasonal Allergic Rhinitis, sponsored by Faes Farma, S.A.. Completed. Open to participants aged 12 Years to 70 Years. Per ClinicalTrials.gov, last updated 2012-04-05.

Sponsored by Faes Farma, S.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
720
Allocation
Randomized
Ages
12 Years to 70 Years
Sex
All
01

Study summary

The objective of the study was to determine the efficacy and tolerability of 20 mg of Bilastine, compared to Desloratadine and placebo for the treatment of Seasonal Allergic Rhinitis.

Read the detailed description

Pivotal, double-blind, randomized, placebo-controlled, comparative with desloratadine, parallel group, international, multicenter study.The Primary endpoint was the Change in total reflective score on the scale of symptoms associated with seasonal allergic rhinitis indicated by patients at the baseline assessment and over the 2 weeks of the study. A total of 720 patients with seasonal allergic rhinitis were enrolled. Duration of treatment was 14 days, preceded by one week (7 days) of placebo.

02

Conditions studied

  • Seasonal Allergic Rhinitis

Keywords

  • Rhinitis
  • Allergic
  • Seasonal
  • Hay Fever
  • Pollen Allergy
  • Pollinosis
  • Rhinoconjunctivitis
  • Sneezing
  • Nasal itching
  • Nasal Congestion
  • Rhinorrhea
  • Ocular itching
  • Ocular redness
  • Tearing
03

In context

Rhinitis, Allergic, Seasonal

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

This study's enrollment of 720 is above the median of 131 across 366 interventional studies indexed under Rhinitis, Allergic, Seasonal.

Browse Rhinitis, Allergic, Seasonal studies →

Lead sponsor

Faes Farma, S.A. is the lead sponsor of 17 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The study disease was diagnosed on the basis of clinical criteria: Nasal symptoms (presence of nasal blockage, sneezing, nasal itching and rhinorrhea) and non-nasal symptoms (ocular itching, lacrimation, itching of ears and/or palate and ocular redness), as well as the skin prick test performed at the time of selection or within the year prior to entering.
  • Patients with history of Seasonal Allergic Rhinitis, positive skin prick test and symptoms were included if they were between 12 and 70 years old, gave their , attended the required visits scheduled and also underwent a complete medical examination..

Exclusion criteria

Exclusion Criteria:

  • Patients were excluded if they had a significant nasal abnormality which could interfere with the aim of the study, acute or chronic sinusitis, asthma or any condition, disease or that could be harmed.
  • Patients were not allowed to take forbidden medications or not comply the study requirements.
  • Patients who were currently participating in or had participated in another clinical trial within the previous three months or were planning to travel outside of the study area during the course of the study were excluded.
  • Pregnant or breast-feeding women were also excluded.
  • Women of had a pregnancy test done
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
720 participants (actual)

Study arms

  • Experimental
    Bilastine

    Drug: Bilastine

  • Active comparator
    Desloratadine

    Drug: Desloratadine

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • 20 mg (encapsulated) tablets QD/14 days

  • 5 mg (encapsulated) tablets QD/14 days

    Also known as: Aerius

  • DrugPlacebo

    (encapsulated) Tablets QD/14 days

06

What researchers measure

Primary outcomes

  1. AUC of TSS

    The area under curve (AUC) of the total symptom score (TSS) since basal visit to D14 visit according to the patient's assessment.

    Time frame: 14 days

Secondary outcomes

  1. Change in TSS. Reflective symptoms

    Change in the reflective total score on symptom scale on D14 visit and day7 visit versus D0 visit (baseline) according to the patient´s assessment on the previous 12 hours.

    Time frame: 14 days

  2. Change in TSS. Instantaneous score

    Change in the total score on symptom scale on D7 and D14 visits versus D0 visit (baseline) according to the patient's assessment (instantaneous score).

    Time frame: 14 days

  3. Change in total nasal symptom score (TNSS)

    Change in nasal symptom score on symptom scale on D7 and D14 visits versus D0 visit (baseline) according to the patient's and investigator's assessment.

    Time frame: 14 days

  4. Change in total non-nasal symptom score (TNNSS)

    Change in non-nasal symptom score on symptom scale on D7 and D14 visits versus D0 visit (baseline) according to the patient's and investigator's assessment

    Time frame: 14 days

  5. VAS of discomfort

    Overall assessment of discomfort caused by allergic rhinitis using a visual analog scale (VAS) on D7 and D14 versus D0.

    Time frame: 14 days

  6. CGI

    Investigator's overall clinical impression (CGI)

    Time frame: 14 days

  7. Allergic rhinitis (AR) quality of life (QoL) questionnaire

    Quality of Life change versus baseline.

    Time frame: 14 days

  8. Onset of action

    Symptoms assessment in the first 48 hours since the beginning of the treatment

    Time frame: 2 days

  9. Safety assessment

    comparison of the adverse event profiles throughout the course of the study, ECGs and safety blood tests on D0 and D14.

    Time frame: 14 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Bachert C, Kuna P, Sanquer F, Ivan P, Dimitrov V, Gorina MM, van de Heyning P, Loureiro A; Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy. 2009 Jan;64(1):158-65. doi: 10.1111/j.1398-9995.2008.01813.x. PubMed 19132976 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2003, a primary completion of Aug 2003 and a completion of Feb 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2010
First posted
Apr 22, 2010
Start
Apr 2003
Primary completionActual
Aug 2003
CompletionActual
Feb 2004
Last update
Apr 5, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01108783
Lead sponsor
Faes Farma, S.A.
Responsible party
Sponsor
First posted
Apr 22, 2010
Start date
Apr 2003
Primary completion
Aug 2003
Completion
Feb 2004
Last update
Apr 5, 2012

Study contacts

Piotr Kuna, Prof. Dr.
principal investigator · Barlicki University Hospital, Medical University of Lodz (Poland)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bilastine

Start the discussion